Data presented at the American Society of Clinical Oncology (ASCO) meeting show that the combination of olaparib plus cediranib may have greater effects on progression-free survival (PFS) than either agent alone when used as maintenance therapy in platinum-sensitive ovarian cancer. An exploratory analysis suggests adding cediranib to olaparib may have a more pronounced